Kara Swisher is taking on the booming longevity industry in a new six-part series that starts April 11 at 9 p.m. ET/PT. The docuseries, which runs on six consecutive Saturdays and ends May 16, puts anti-aging treatments, biohacking and wellness claims under the same lens.
Swisher does not stay behind the camera. She tests ketamine, red light and sound therapy herself, and interviews Bryan Johnson, Sam Altman and Scott Galloway as she separates fact from fad in the longevity craze. The series asks who actually benefits from the race to live longer, and who gets left behind.
That question sits at the center of the project. The series examines how wealth, access to healthcare and social connection shape who can reach longevity breakthroughs, turning a consumer trend into a question about inequality as much as aging. In that way, the show lands today as a portrait of a booming market and a narrowing divide.
The tension is that the industry sells a future built on science, but the benefits are not equally available. The series tackles treatments that are marketed as progress while also showing how much of that progress depends on money, medical access and even the size of a person’s social world. It is a test of both the claims and the culture around them.
For viewers who want to watch live, is available through DirecTV, Sling and Hulu + Live TV. DirecTV includes in its Entertainment, Choice, Ultimate and Premier packages and offers a five-day free trial for its streaming service. Sling’s Blue Plan and Orange Plan both carry and start at $45.99 a month, while the Orange & Blue plan starts at $60.99. Hulu + Live TV starts at $89.99 a month, offers a three-day trial and is bundled with Disney+ and +.
Swisher’s series does not just ask whether longevity science works. It asks who gets to try it, who gets to afford it and whether the promise of a longer life is really a promise for everyone.